Impact of L-carnitine supplementation on lipid profile parameters in overweight and obese women: a systematic review and meta-analysis of randomized controlled trials Authors: Yongmei Yu, Dongping Xu, Siyi Shang, Yuanxia Liu, Zhengxian Qian Published: 2026 ABSTRACT Background and aimL-carnitine plays a central role in fatty acid metabolism and has been proposed as a potential strategy for improving lipid regulation. However, evidence from clinical trials remains inconsistent, and female-specific data are scarce. This systematic review and meta-analysis aimed to evaluate the effects of L-carnitine supplementation on lipid profiles specifically in women with overweight or obesity.MethodsA systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted in accordance with PRISMA guidelines. Eligible studies enrolled women with BMI ≥ 25 kg/m² and compared L-carnitine supplementation with placebo or no intervention. Pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using a random-effects model.ResultsTen RCTs were included. L-carnitine supplementation significantly reduced TG (WMD: − 8.01 mg/dL; 95%CI: − 15.21 to − 0.81), TC (WMD: − 7.85 mg/dL; 95%CI: − 14.54 to − 1.16), and LDL-C (WMD: − 5.59 mg/dL;95%CI: − 10.02 to − 1.16). No significant overall effect was found for HDL-C (WMD:1.09 mg/dL;95%CI: − 1.79 to 3.99). Subgroup analyses indicated stronger effects at higher doses, shorter intervention durations, and in participants with elevated baseline lipid levels.ConclusionL-carnitine supplementation provides significant improvements in TG, TC, and LDL-C among overweight and obese women, although HDL-C responses remain inconsistent. These findings suggest a potential adjunctive role for L-carnitine in cardiometabolic risk management.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12986-026-01159-4. Introduction Obesity is correlated to increased cardiovascular diseases (CVDs) due to the development of atherogenic dyslipidemia, which is characterized by an adverse lipid profile, including elevated triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), and dense low-density lipoprotein cholesterol (LDL-C) particles [1]. This link between adiposity and CVD emphasizes the urgent need for effective strategies to mitigate this risk [2, 3]. For women, this risk is uniquely controlled due to their physiology [4]. Premenopausal women often have a more favorable lipid profile than men [5]; however, this advantage is frequently lost with the onset of conditions such as polycystic ovary syndrome and menopause [6, 7]. This makes overweight and obese women a critical clinical population to observe [8, 9]. Sex based differences in lipid metabolism are well established and extend beyond differences in body composition alone [10]. Women, particularly in the premenopausal period, tend to exhibit higher circulating HDL-C concentrations, enhanced LDL receptor mediated clearance, and greater reliance on lipid oxidation compared with men, largely mediated by estrogen signaling [7, 11]. Estrogen influences hepatic lipoprotein metabolism, mitochondrial fatty acid oxidation, and adipose tissue lipid partitioning, contributing to sex-specific lipid profiles and cardiometabolic risk trajectories [12]. Because L-carnitine exerts its effects primarily through mitochondrial fatty acid transport and oxidation, sex-related differences in mitochondrial function, substrate utilization, and hormonal regulation may influence responsiveness to supplementation. Women generally exhibit high reliance on lipid oxidation than men [13], suggesting that the metabolic consequences of enhanced fatty acid transport may not be identical across sexes. These physiological differences highlight the importance of evaluating lipid-modifying interventions within sex-specific contexts rather than extrapolating from mixed-sex analyses. Among potential interventions, L-carnitine, an essential quaternary ammonium compound vital for fatty acid metabolism, stands as a promising solution [14]. L-carnitine functions to transport long-chain fatty acids into the mitochondrial matrix for β-oxidation [15], a process essential for energy production [16]. Additionally, L-carnitine may regulate lipid profiles by controlling the intramitochondrial ratio of acyl-coenzyme A (CoA) to free CoA [17], which can affect the rate of lipogenesis and the secretion of very- LDL) [18]. Furthermore, it has been suggested to improve overall mitochondrial function and reduce inflammation [19], giving several reasons why it could be useful for treating dyslipidemia [20]. Given L-carnitine’s central role in mitochondrial fatty acid transport and β-oxidation, sex-related differences in mitochondrial metabolism and hormonal regulation may plausibly influence responsiveness to supplementation, further supporting the need for female-specific evaluation. Although L-carnitine has a strong biological basis for improving lipid levels, its effectiveness in clinical trials has been inconsistent [21, 22]. Past meta-analyses show different results depending on the group studied: for instance, patients with type 2 diabetes saw reductions in total cholesterol (TC) and LDL-C [23], patients with liver disease showed improvements in TC and TG [24], and hemodialysis patients only had reductions in LDL-C [25]. These differences likely reflect variations in study design, patient populations, and treatment protocols [26, 27]. A key feature in the existing literature is that most randomized trials of L-carnitine in overweight and obese populations have been conducted almost entirely in women [8, 9]. To date, the evidence from female-focused trials on L-carnitine has not been systematically reviewed. Previous quantitative analyses have either combined female-only studies with mixed-sex cohorts or concentrated on populations with other health conditions, which may obscure sex-specific effects [21, 22]. Due to the well-documented sex-based differences in lipid metabolism and the predominance of female participants in the existing trials, a targeted synthesis is needed [28]. Although some included participants had comorbid conditions such as polycystic ovary syndrome (PCOS), type 2 diabetes, or osteoarthritis, all trials enrolled women with overweight or obesity, allowing evaluation of L-carnitine supplementation within a more homogeneous sex-specific framework than previous meta-analyses. To our knowledge, this is the first systematic review and meta-analysis specifically focused on overweight and obese women. By pooling available evidence, this analysis seeks to clarify the efficacy of L-carnitine in this population, explore potential sources of variability, and provide practical insights for clinicians and researchers regarding its role as a complementary strategy in obesity management. Therefore, the primary objective of our systematic review and meta-analysis was to evaluate the effects of L-carnitine supplementation on lipid parameters in women with overweight or obesity. We hypothesized that L-carnitine supplementation would improve lipid profile parameters, particularly among women with adverse baseline lipid concentrations. Materials and methods Study design and reporting framework This study was conducted as a systematic review and meta-analysis of randomized controlled trials assessing the effects of L-carnitine supplementation on lipid profile parameters in women with overweight or obesity. The review process followed the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to ensure transparent identification, screening, eligibility assessment, and inclusion of relevant studies [29]. Literature search strategy A comprehensive electronic search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and Embase to identify relevant trials published through August 27, 2025. The search approach integrated both controlled vocabulary (e.g., MeSH terms) and free-text keywords pertaining to carnitine and lipid metabolism. The strategy incorporated combinations of the following terms: (“L-Carnitine“[Mesh] OR l-carnitine[tiab] OR carnitine[tiab] OR levocarnitine[tiab]) AND (women[tiab] OR female[tiab] OR females[tiab] OR “Women“[Mesh]) AND (“Clinical Trial“[Publication Type] OR “Randomized Controlled Trial“[Publication Type] OR randomized[tiab] OR randomised[tiab] OR trial[tiab] OR RCT[tiab] OR placebo[tiab] OR “double-blind“[tiab] OR “single-blind“[tiab] OR “cross-over“[tiab] OR “intervention“[tiab]) (Supplementary Table 1). No limitations were imposed with respect to language or year of publication. Furthermore, the reference lists of all included articles and relevant review papers were manually screened to identify any additional studies that might meet the eligibility criteria. Eligibility criteria Study selection was guided by the PICOS framework. Eligible studies met the following criteria: (1) population: adult women classified as overweight or obese (BMI ≥ 25 kg/m²); (2) intervention: supplementation with L-carnitine or related carnitine compounds; (3) comparator: placebo or no-treatment control group; (4) outcomes: reporting baseline and post-intervention values for at least one lipid parameter, including TC, TG, HDL-C, or LDL-C; and (5) study design: randomized controlled trials. Studies were excluded if they were observational, reviews, editorials, animal studies, lacked a control group, did not provide sufficient quantitative lipid data, or enrolled mixed-sex populations without extractable female-specific results. Study selection process After removing duplicate records, two investigators independently screened titles and abstracts for relevance. Articles that appeared eligible were subsequently evaluated in full text. Any disagreements during screening or eligibility assessment were resolved through discussion and, when necessary, consultation with a senior author to reach consensus. Data extraction Data were independently extracted by two reviewers using a standardized extraction form. Information collected included first author, publication year, country, sample size, participants’ age and BMI, health condition, intervention dose and duration, and study design characteristics. For outcomes, mean values and standard deviations of TG, TC, HDL-C, and LDL-C at baseline and at the end of the intervention were recorded for both intervention and control groups. When discrepancies occurred, they were resolved through rechecking the original article and discussion among the investigators. Risk of bias and certainty of evidence Methodological quality of the included trials was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool, which assesses randomization procedures, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting. Each study was categorized as having low risk, some concerns, or high risk of bias [30, 31]. The overall certainty of evidence for each lipid outcome was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, considering study limitations, inconsistency, indirectness, imprecision, and potential publication bias [31]. Statistical analysis All statistical analyses were conducted using Stata version 15 (StataCorp, College Station, TX, USA). Effect sizes were calculated as weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs). A DerSimonian–Laird random-effects model was applied to account for between-study variability [32, 33]. When change-score standard deviations were not reported, they were estimated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned}&\mathrm{SD}\_\mathrm{change}\\ &\quad=\surd[(\mathrm{SD}\_\mathrm{baseline}^2+\mathrm{SD}\_\mathrm{final}^2)\\ &\qquad-(2\times\:R\times\:\mathrm{SD}\_\mathrm{baseline}\times\mathrm{SD}\_\mathrm{final})],\end{aligned}$$\end{document} where R represents the assumed correlation coefficient between baseline and follow-up measurements. Consistent with previous nutrition meta-analyses, an R value of 0.5 was assumed when not reported by the original study. Sensitivity analyses using alternative assumptions yielded similar conclusions. Statistical significance was defined as P < 0.05. Heterogeneity across studies was assessed using Cochran’s Q test and the I² statistic, with I² values of < 30%, 30–75%, and > 75% indicating low, moderate, and high heterogeneity, respectively. Prespecified subgroup analyses were performed based on dose, intervention duration, and baseline lipid concentrations to explore potential sources of heterogeneity. Subgroup categories were prespecified according to clinically relevant thresholds for dose (< 1000, 1000–2000, and ≥ 2000 mg/day), intervention duration (< 12 versus ≥ 12 weeks), and baseline lipid concentrations based on conventional clinical cut-points. Sensitivity analyses were conducted by removing one study at a time to test the robustness of pooled estimates [34]. Publication bias was evaluated visually using funnel plots and statistically using Egger’s regression test. When asymmetry was suspected, the trim-and-fill method was applied to examine the potential influence of missing studies on the overall results [35]. Results Study selection The initial database search yielded 3,221 records. As outlined in Figs. 1 and 536 duplicates were removed, leaving 2,685 unique studies. After screening titles and abstracts, these were excluded for not meeting the eligibility criteria. A total of 32 articles were retrieved for full-text assessment, of which 9 articles comprising 10 trials met the inclusion criteria for the final meta-analysis. Among these trials, 10 study arms reported outcomes for HDL cholesterol, 10 for LDL cholesterol, 10 for TC, and 10 for TG [8, 9, 36–42]. Fig. 1Flow chart for study examined and included into the meta-analysis Flow chart for study examined and included into the meta-analysis Characteristics of the included studies A comprehensive overview of the study attributes is presented in Table 1. This review included ten randomized controlled trials conducted between 2011 and 2022 across Iran, Iraq, and Kuwait. All studies recruited women, most of whom were overweight or obese, with clinical conditions such as polycystic ovary syndrome, knee osteoarthritis, or type 2 diabetes. The mean age of participants ranged from 24.8 to 55.0 years. Table 1Characteristics of eligible studiesAuthor, yearCountryAge (years)PopulationSample sizeintervention/placeboBMIDurationOutcomeIntervention dosage (mg/day)Sangouni et al. 2022Iran30.7Overweight/obese women with Polycystic Ovary Syndrome (PCOS)28/283112 wksTG, TC, HDL-C, LDL-C1000 mg/dayBaghban et al. 2021Iran55.01Obese women with knee osteoarthritis (KOA)34/3633.0312wksTG, TC, HDL-C, LDL-C1000 mg/day L-carnitineHassani et al. 2018Iran53.6Women with type 2 diabetes10/1031.88 wksTG, HDL-C, LDL-C500 mg/day L-carnitineSamimi et al. 2016Iran24.8Overweight women with polycystic ovary syndrome (PCOS)30/3029.112 wksTG, TC, HDL-C, LDL-C250 mg carnitineMosah et al. 2015Iraq33.11Obese Iraqi females18/1834.5912wksTG, TC, HDL-C, LDL-C1000 mg/dayMalek Mahdavi et al. 2015Iran51.63Overweight or obese females with mild to moderate knee osteoarthritis33/3631.578wksTG, TC, HDL-C, LDL-C750 mg/dayAlipoor et al. 2014Iran37.03Obese premenopausal women with type II diabetes30/3033.48wksTG, TC, HDL-C, LDL-C2000 mg/day (administered as 1000 mg twice daily)Karimi(a) et al. 2013Iran34.4Obese women11/1133.98wksTG, TC, HDL-C, LDL-C2000 mg/day L-carnitineKarimi(b) et al. 2013Iran34.4Obese women11/1133.98wksTC, LDL-C2000 mg/day L-carnitineAlshammari et al. 2011Kuwait52.1Obese women10/1031.38 wksTG, TC, HDL-C4 mg/kg body weight, every other day Table 1Characteristics of eligible studiesAuthor, yearCountryAge (years)PopulationSample sizeintervention/placeboBMIDurationOutcomeIntervention dosage (mg/day)Sangouni et al. 2022Iran30.7Overweight/obese women with Polycystic Ovary Syndrome (PCOS)28/283112 wksTG, TC, HDL-C, LDL-C1000 mg/dayBaghban et al. 2021Iran55.01Obese women with knee osteoarthritis (KOA)34/3633.0312wksTG, TC, HDL-C, LDL-C1000 mg/day L-carnitineHassani et al. 2018Iran53.6Women with type 2 diabetes10/1031.88 wksTG, HDL-C, LDL-C500 mg/day L-carnitineSamimi et al. 2016Iran24.8Overweight women with polycystic ovary syndrome (PCOS)30/3029.112 wksTG, TC, HDL-C, LDL-C250 mg carnitineMosah et al. 2015Iraq33.11Obese Iraqi females18/1834.5912wksTG, TC, HDL-C, LDL-C1000 mg/dayMalek Mahdavi et al. 2015Iran51.63Overweight or obese females with mild to moderate knee osteoarthritis33/3631.578wksTG, TC, HDL-C, LDL-C750 mg/dayAlipoor et al. 2014Iran37.03Obese premenopausal women with type II diabetes30/3033.48wksTG, TC, HDL-C, LDL-C2000 mg/day (administered as 1000 mg twice daily)Karimi(a) et al. 2013Iran34.4Obese women11/1133.98wksTG, TC, HDL-C, LDL-C2000 mg/day L-carnitineKarimi(b) et al. 2013Iran34.4Obese women11/1133.98wksTC, LDL-C2000 mg/day L-carnitineAlshammari et al. 2011Kuwait52.1Obese women10/1031.38 wksTG, TC, HDL-C4 mg/kg body weight, every other day Characteristics of eligible studies Sample sizes were relatively small, varying between 20 and 70 participants, with intervention and placebo groups generally comparable. Intervention periods ranged from 8 to 12 weeks. Most trials evaluated L-carnitine supplementation, with daily doses ranging from 250 mg to 2000 mg, while one study used a weight-based regimen of 4 mg/kg every other day. Baseline body mass index values fell within the overweight to obese range (29.1–34.6 kg/m²). The main outcomes assessed included lipid profile markers such as TG, TC, HDL-C, and LDL-C. Supplementary Table 2 provides an evaluation of the risk of bias using the Cochrane framework. The majority of included studies demonstrated a low overall risk of bias. Eight studies were rated as low risk. Two studies raised some concerns: Alipoor et al. (2014) was rated as “some concerns” due to insufficient information regarding deviations from intended interventions (D2), and Alshammari et al. (2011) raised some concerns in the randomization process domain (D1). Overall, the included trials were of satisfactory methodological quality, supporting the reliability of the pooled estimates in this meta-analysis. According to the GRADE framework, the certainty of evidence was rated as moderate for TG, TC, and LDL-C outcomes, indicating moderate confidence that L-carnitine supplementation leads to modest reductions in these lipid parameters in overweight and obese women. The certainty of evidence for HDL-C was rated as low, primarily due to high heterogeneity and imprecision across studies (Supplementary Table 3). Meta-analysis findings Effect on TG levels A total of 10 study arms, including 435 women with overweight or obesity (215 intervention, 220 control), demonstrated that L-carnitine supplementation significantly reduced serum TG levels (WMD: − 8.01 mg/dL; 95% CI: − 15.21 to − 0.81; P = 0.029). Considerable heterogeneity was observed (I² = 60.8%, P = 0.008) (Fig. 2). Subgroup analyses revealed greater reductions at doses ≥ 2000 mg/day (WMD: − 11.77 mg/dL; 95% CI: − 20.86 to − 2.67; P = 0.011) and < 1000 mg/day (WMD: − 10.48 mg/dL; 95% CI: − 19.57 to − 1.38; P = 0.024), whereas doses of 1000–2000 mg/day were not effective (WMD: − 1.22 mg/dL; 95% CI: − 19.51 to 17.07; P = 0.896). Baseline TG levels also influenced outcomes: participants with TG ≥ 150 mg/dL experienced significant reductions (WMD: − 9.74 mg/dL; 95% CI: − 15.77 to − 3.70; P = 0.002), while those with TG < 150 mg/dL did not (WMD: − 7.50 mg/dL; 95% CI: − 22.33 to 7.33; P = 0.322). Treatment duration was another modifier, interventions < 12 weeks significantly reduced TG (WMD: − 9.90 mg/dL; 95% CI: − 16.27 to − 3.54; P = 0.002), whereas those ≥ 12 weeks showed no effect (WMD: − 5.92 mg/dL; 95% CI: − 22.48 to 10.63; P = 0.483) (Supplementary Fig. 1). Fig. 2Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on serum triglycerides (TG). WMD, weighted mean difference; CI, confidence interval; TG, serum triglycerides Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on serum triglycerides (TG). WMD, weighted mean difference; CI, confidence interval; TG, serum triglycerides Effect on TC levels Analysis of 10 study arms (435 women with overweight or obesity) showed that L-carnitine supplementation significantly lowered TC (WMD: − 7.85 mg/dL; 95% CI: − 14.54 to − 1.16; P = 0.021), with high heterogeneity (I² = 74.5%, P < 0.001) (Fig. 3). Short-term interventions (< 12 weeks) led to significant reductions (WMD: − 12.60 mg/dL; 95% CI: − 22.61 to − 2.60; P = 0.013), whereas longer interventions (≥ 12 weeks) did not (WMD: − 1.26 mg/dL; 95% CI: − 10.04 to 7.51; P = 0.778). Participants with baseline TC ≥ 200 mg/dL benefited more (WMD: − 14.73 mg/dL; 95% CI: − 22.12 to − 7.34; P < 0.001), while those with TC < 200 mg/dL showed no meaningful change (WMD: − 1.32 mg/dL; 95% CI: − 7.54 to 4.89; P = 0.676). Fig. 3Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on total cholesterol (TC). WMD, weighted mean difference; CI, confidence interval; TC, total cholesterol Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on total cholesterol (TC). WMD, weighted mean difference; CI, confidence interval; TC, total cholesterol Dose stratification indicated a significant effect at ≥ 2000 mg/day (WMD: − 11.72 mg/dL; 95% CI: − 20.61 to − 2.82; P = 0.010), but not at < 1000 mg/day (WMD: − 8.68 mg/dL; 95% CI: − 21.54 to 4.17; P = 0.186) or 1000–2000 mg/day (WMD: − 4.47 mg/dL; 95% CI: − 13.49 to 4.54; P = 0.331) (Supplementary Fig. 1). Effect on high-density HDL-C levels Across 10 study arms (435 women with overweight or obesity), L-carnitine supplementation produced a non-significant increase in HDL-C (WMD: 1.09 mg/dL; 95% CI: − 1.79 to 3.99; P = 0.457), with substantial heterogeneity (I² = 85.6%, P < 0.001) (Fig. 4). Subgroup analysis showed that participants with baseline HDL-C ≥ 50 mg/dL experienced a significant decrease (WMD: − 4.03 mg/dL; 95% CI: − 7.20 to − 0.86; P = 0.013), whereas those with HDL-C < 50 mg/dL exhibited no significant change (WMD: 2.49 mg/dL; 95% CI: − 0.52 to 5.51; P = 0.105) (Supplementary Fig. 1). Fig. 4Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on HDL-C. WMD, weighted mean difference; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on HDL-C. WMD, weighted mean difference; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol Effect on LDL-C levels In 10 study arms (435 women with overweight or obesity), L-carnitine supplementation significantly reduced LDL-C levels (WMD: − 5.59 mg/dL; 95% CI: − 10.02 to − 1.16; P = 0.013), with moderate heterogeneity (I² = 59%, P = 0.009) (Fig. 5). Participants with baseline LDL-C ≥ 130 mg/dL showed greater benefit (WMD: − 6.73 mg/dL; 95% CI: − 9.81 to − 3.65; P < 0.001), while those with LDL-C < 130 mg/dL did not (WMD: − 2.82 mg/dL; 95% CI: − 13.76 to 8.12; P = 0.613). Duration mattered: interventions < 12 weeks were effective (WMD: − 6.78 mg/dL; 95% CI: − 9.74 to − 3.81; P < 0.001), but those ≥ 12 weeks were not (WMD: − 3.22 mg/dL; 95% CI: − 16.01 to 9.56; P = 0.622). Dose analysis showed significant reductions at ≥ 2000 mg/day (WMD: − 6.05 mg/dL; 95% CI: − 10.13 to − 1.98; P = 0.004), but no effect at < 1000 mg/day (WMD: − 2.51 mg/dL; 95% CI: − 11.18 to 6.15; P = 0.570) or 1000–2000 mg/day (WMD: − 6.81 mg/dL; 95% CI: − 21.28 to 7.66; P = 0.357) (Supplementary Fig. 1). Fig. 5Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on LDL-C. WMD, weighted mean difference; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol Forest plot of randomized controlled trials investigating the effects of carnitine supplementation on LDL-C. WMD, weighted mean difference; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol Sensitivity analyses, publication bias and meta-regression Sensitivity analyses, conducted by sequentially omitting individual studies, confirmed that no single study unduly influenced the pooled results (Supplementary Fig. 2). Publication bias was assessed using funnel plots and Egger’s regression test. Visual inspection of funnel plots followed by trim-and-fill analysis revealed no evidence of potentially missing or unpublished studies for any lipid outcomes (LDL-C, TC, HDL-C, or TG), and the pooled effect estimates remained unchanged after adjustment (Supplementary Fig. 3). Subsequent meta-regression analysis examining the relationship between intervention duration and L-carnitine dosage in relation to lipid profile alterations revealed no significant association (Supplementary Fig. 4). Discussion This systematic review and meta-analysis demonstrates that L-carnitine supplementation leads to modest but statistically significant reductions in serum TG, TC, and LDL-C in women with overweight or obesity, while no overall effect was observed on HDL-C. Importantly, subgroup analyses revealed that these effects were not uniform but varied according to baseline lipid status, dosage, and intervention duration, underscoring the context-dependent nature of L-carnitine’s lipid-modulating actions. The moderate-to-high heterogeneity observed for several outcomes, particularly TC and HDL-C, likely reflects both clinical and methodological variability among the included trials. Participants differed with respect to underlying conditions (e.g., PCOS, type 2 diabetes, osteoarthritis), baseline lipid concentrations, age, and metabolic status, all of which may influence responsiveness to L-carnitine supplementation. Methodological differences, including dosage regimens, treatment duration, and variation in background dietary and lifestyle interventions, may have further contributed to between-study variability. Although subgroup and meta-regression analyses identified baseline lipid levels, dosage, and duration as potential modifiers, residual heterogeneity remained, suggesting that unmeasured factors may also influence treatment response. The mechanistic explanations provided in this discussion are hypothesis-generating, as the included trials did not directly assess molecular or functional pathways related to lipid metabolism. The most consistent finding was the reduction in TG levels, particularly among women with elevated baseline TG concentrations and in trials using higher doses or shorter intervention durations. This pattern is mechanistically plausible given L-carnitine’s central role in mitochondrial fatty acid transport and β-oxidation [14–16]. By facilitating the translocation of long-chain fatty acids into mitochondria, L-carnitine reduces the cytosolic fatty acid pool available for hepatic TG synthesis and subsequent VLDL secretion [17, 18]. In states of obesity and insulin resistance, conditions characterized by hepatic lipid overload and increased VLDL production, this mechanism provides a biologically coherent explanation for the preferential TG-lowering effect observed in our analysis. The stronger TG reductions seen in participants with higher baseline TG levels further support a substrate-dependent response, whereby individuals with greater lipid flux derive greater metabolic benefit from enhanced fatty acid oxidation. The concurrent reductions in TC and LDL-C, although smaller in magnitude, appear to reflect complementary mechanisms beyond simple TG lowering. In addition to promoting fatty acid catabolism, L-carnitine modulates the intramitochondrial acyl-CoA to free CoA ratio, thereby improving mitochondrial metabolic flexibility and potentially influencing hepatic lipid handling [14, 17]. Emerging experimental evidence suggests that carnitine and its derivatives may also downregulate the sterol regulatory element-binding protein 2 (SREBP2) pathway, a master regulator of endogenous cholesterol biosynthesis [43]. Suppression of SREBP2 and its downstream targets, including HMG-CoA reductase, represents a putative molecular mechanism that requires confirmation in human studies. The greater cholesterol-lowering effects observed in participants with elevated baseline TC or LDL-C are consistent with this regulatory model, as dysregulated cholesterol homeostasis may be more amenable to intervention in metabolically compromised states. Comparison with prior meta-analyses further highlights the population-specific nature of L-carnitine’s lipid effects. In patients with type 2 diabetes, previous syntheses reported significant reductions in TC and LDL-C but minimal effects on TG [23], whereas in liver disease, where hepatic steatosis and VLDL overproduction are prominent, larger TG and TC reductions were observed [24]. In contrast, hemodialysis patients showed little to no lipid response [25]. The pattern observed in our study, simultaneous reductions in TG, TC, and LDL-C, closely resembles findings in women with PCOS, a condition characterized by insulin resistance, dyslipidemia, and altered mitochondrial metabolism [9, 44]. Several included trials enrolled women with PCOS, suggesting that overlapping metabolic disturbances may partly explain the consistency of effects in this female-specific population. Collectively, these comparisons reinforce the concept that L-carnitine’s efficacy is contingent on the dominant metabolic derangements of the target population rather than representing a universal lipid-lowering agent. Our findings may also be viewed in the context of a previous meta-analysis by Sheiki et al. [45], which reported that L-carnitine does not change Apo B100 and Apo AI concentration. Our review differs in both population and outcome focus, as it specifically evaluates overweight and obese women and examines conventional lipid profile parameters rather than apolipoproteins. Together, these findings suggest that L-carnitine may exert modest effects on traditional lipid measures while having limited influence on circulating apolipoprotein concentrations. A notable and unexpected finding was the significant reduction in HDL-C among women with high baseline HDL-C levels (≥ 50 mg/dL), despite no overall effect on HDL-C in the pooled analysis. At face value, this result appears paradoxical given HDL’s established cardioprotective role. However, this observation can be contextualized by considering HDL functionality rather than concentration alone. HDL-C levels represent a static measure and do not capture the dynamic processes of reverse cholesterol transport (RCT) or HDL particle turnover [46]. One speculative explanation is that by enhancing fatty acid oxidation and lipid flux, L-carnitine accelerates RCT, leading to increased clearance and turnover of HDL particles. This would manifest as a lower circulating HDL-C concentration while potentially reflecting more efficient cholesterol efflux rather than impaired cardioprotection. Additionally, alterations in VLDL secretion and TG metabolism may influence HDL particle remodeling, resulting in smaller, denser HDL particles with faster plasma clearance. Finally, individuals with high baseline HDL-C may harbor large, lipid-rich but dysfunctional HDL particles, particularly in the context of insulin resistance, such that L-carnitine preferentially promotes the remodeling or clearance of these less effective particles. This interpretation aligns with growing evidence that HDL function, rather than absolute HDL-C concentration, is the more relevant determinant of cardiovascular risk [46]. Nevertheless, this finding should be interpreted cautiously. The subgroup result was derived from a limited number of studies and may reflect regression toward the mean, baseline metabolic differences, or random variation. Because HDL functionality, particle size, and cholesterol efflux capacity were not measured in the included trials, it is not possible to determine whether the observed reduction represents a favorable or unfavorable biological response. Dose- and duration-dependent effects observed in this meta-analysis further support a mechanistic interpretation of the findings. Higher doses (≥ 2000 mg/day) and shorter intervention durations (< 12 weeks) were associated with more pronounced lipid improvements, whereas intermediate doses and longer durations showed attenuated or null effects. This pattern may reflect early metabolic adaptations to enhanced fatty acid oxidation that plateau over time, or compensatory regulatory mechanisms that limit sustained lipid changes with prolonged supplementation. Alternatively, shorter trials may preferentially capture acute improvements in lipid handling before homeostatic feedback mechanisms are engaged. These considerations highlight the importance of optimizing dosing strategies in future trials rather than assuming linear dose–response relationships. Clinical implications From a clinical perspective, the magnitude of lipid reductions observed in this analysis is modest. The average LDL-C reduction of approximately 5.6 mg/dL would correspond to an estimated 3% relative reduction in major adverse cardiovascular events based on established epidemiological relationships [47], a benefit that is unlikely to be clinically meaningful as monotherapy. More broadly, the absolute reductions observed across lipid outcomes were generally less than 10 mg/dL and substantially smaller than those typically achieved with established lipid-lowering pharmacotherapies. Therefore, L-carnitine should not be viewed as a substitute for evidence-based treatments but rather as a potential adjunctive strategy that may provide incremental benefit in selected populations. However, within a broader lifestyle or multimodal intervention framework, such incremental improvements may still contribute to overall cardiometabolic risk reduction. This is particularly relevant for overweight or obese women with PCOS or related metabolic disturbances, in whom mitochondrial dysfunction and altered lipid partitioning may render L-carnitine supplementation more biologically relevant [48]. L-carnitine serves as a precursor for trimethylamine-N-oxide (TMAO), a gut microbiota-derived metabolite associated with cardiovascular risk [49–51]. However, none of the included trials assessed TMAO levels, limiting the ability to evaluate whether lipid improvements may be counterbalanced by potential adverse metabolic effects. Future RCTs should therefore incorporate both lipid parameters and gut microbiome–related metabolites [52] to provide a more comprehensive assessment of the cardiometabolic effects of L-carnitine supplementation. Overall, these findings suggest limited clinical efficacy as monotherapy and should be interpreted within the context of established lipid-lowering interventions. Strengths and limitations The primary strength of this meta-analysis is its focused scope on a specific demographic (overweight and obese women), which provides much-needed sex-specific data in a research area often dominated by mixed-gender studies. By narrowing the inclusion criteria to this group, our analysis offers more relevant insights for female patients, who can have different metabolic responses to interventions than males. Methodologically, the review adhered to rigorous PRISMA guidelines and included only randomized controlled trials, enhancing the reliability of the findings. We employed the Cochrane RoB 2 tool to assess risk of bias in the included studies and conducted sensitivity analyses to test the robustness of the pooled results. These steps strengthen confidence that the observed effects are not artifacts of bias or analytical choices. The strength of this review does not stem from the use of the RoB 2 tool itself, which represents current best practice for randomized controlled trials, but from the transparent and consistent application of a standardized risk-of-bias framework across all included studies. This approach facilitated a clear assessment of internal validity and informed cautious interpretation of the pooled findings considering identified study limitations. A major limitation affecting the external validity of our findings is the lack of geographical and ethnic diversity among the included trials. All ten RCTs in our meta-analysis were conducted in Middle Eastern countries (Iran, Iraq, and Kuwait). This homogeneity in study locales and participant backgrounds restricts the generalizability of the results to other populations with different genetic backgrounds, lifestyles, and dietary habits. Notably, dietary patterns in the Middle East have been undergoing a transition from traditional diets (high in fiber and plant foods) to more Westernized diets high in animal fat and refined carbohydrates [53, 54]. Such region-specific nutrition transitions could interact with the effects of L-carnitine; for instance, baseline carnitine intake, gut microbiota composition, and metabolic status may differ in ways that influence responsiveness to supplementation. Therefore, the observed lipid effects in Middle Eastern women may not be fully reproducible in women from other regions (e.g., Europe, East Asia, or the Americas) who have different diet gut axis dynamics. Finally, an important omission in the current evidence base is the lack of data on TMAO outcomes in these trials. None of the included studies reported plasma TMAO levels or related metabolites. This precludes any assessment of whether the beneficial lipid changes come at the cost of raising TMAO, a trade-off that, as discussed, could be clinically significant. Future trials would need to capture this information to provide a more comprehensive evaluation of L-carnitine’s net cardiovascular impact. Conclusion L-carnitine supplementation in overweight and obese women produces modest but consistent reductions in TG, TC, and LDL-C, though effects on HDL-C remain inconsistent and context-dependent. These benefits, while not clinically meaningful as a stand-alone therapy, may hold value as an adjunct to lifestyle modification. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5. Supplementary Material 6. Supplementary Material 6. Supplementary Material 7. Supplementary Material 7.